
XOMA (XOMA) Stock Forecast & Price Target
XOMA (XOMA) Analyst Ratings
Bulls say
XOMA Royalty Corp is projected to experience significant revenue growth, with expectations of over 20% annual increases through 2026, largely driven by commercial sales for products such as Vabysmo and new launches like Ojemda and Miplyffa. The company's total income from royalty agreements surged to $28.5 million in 2024, a remarkable rise from $4.8 million in 2023, bolstered by higher revenues from purchased receivables and customer contracts. With forecasts indicating revenues of $49.0 million for 2026, alongside anticipated contributions from earlier-stage assets and milestone payments, XOMA's growth trajectory appears robust, supported by its strategic acquisitions and internal expansion.
Bears say
XOMA Royalty Corp has experienced revenue and net earnings variability due to fluctuations in the international market, which could be further exacerbated by economic downturns, new tariffs, or changes in governmental reimbursement policies. In addition, the company's dependency on unpredictable market conditions and the potential for failed clinical trials or insufficient funding raises concerns about its ability to progress drug development effectively. Furthermore, recent share price declines reflect a reaction to the removal of anticipated near-term revenue drivers, along with broader trends affecting the biotechnology sector, contributing to a negative outlook on the stock.
This aggregate rating is based on analysts' research of XOMA and is not a guaranteed prediction by Public.com or investment advice.
XOMA (XOMA) Analyst Forecast & Price Prediction
Start investing in XOMA (XOMA)
Order type
Buy in
Order amount
Est. shares
0 shares